An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.